Circulating Tumor DNA Analysis Associates with Progression- Free Survival ( PFS) with Odronextamab Monotherapy in Relapsed/Refractory (R/ R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Identification of Minimal Residual Disease Status and High-Risk Subgroups from the Phase 2 ELM-2 Study

被引：1
|
作者：
Arnason, Jon E. [1 ]
Brouwer-Visser, Jurriaan [2 ]
Luminari, Stefano [3 ]
Tucker, David [4 ]
Kim, Tae Min [5 ]
Kim, Won Seog [6 ]
Magnano, Laura [7 ]
Sun, Dylan [2 ]
Cai, Jessica [2 ]
Cygan, Kamil [2 ]
Ambati, Srikanth [2 ]
Mohamed, Hesham [2 ]
Chaudhry, Aafia [2 ]
Jankovic, Vladimir [2 ]
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA USA
[2] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[3] Azienda Unita Sanit Locale IRCCS, Reggio Emilia, Italy
[4] Royal Cornwall Hosp, Truro, Cornwall, England
[5] Seoul Natl Univ Hosp, Seoul, South Korea
[6] Samsung Med Ctr, Ctr Hematol Malignancy, Seoul, South Korea
[7] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-179812
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Ayyappan, Sabarish
    Kim, Won Seog
    Kim, Tae Min
    Walewski, Jan
    Cho, Seok-Goo
    Jarque, Isidro
    Iskierka-Jazdzewska, Elzbieta
    Poon, Michelle
    Oh, Sung Yong
    Lim, Francesca Lorraine Wei Inng
    Carpio, Cecilia
    Tan, Tran-Der
    Gutierrez, Antonio
    Zhang, Huilai
    Cao, Junning
    Zhang, Mingzhi
    Tessoulin, Benoit
    Li, Jingjin
    Ufkin, Melanie
    Shariff, Saleem
    Chi, Lei
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth
    Prince, H. Miles
    BLOOD, 2023, 142
  • [2] Odronextamab Monotherapy for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Focus on Clinical Pharmacology and Pharmacometrics in the ELM-1 and ELM-2 Studies
    Zhu, Min
    Conrado, Daniela
    Srinivasan, Kamal
    Brouwer-Visser, Jurriaan
    Yan, Hong
    Mohamed, Hesham
    Chaudhry, Aafia
    Ambati, Srikanth
    Harnisch, Lutz
    Davis, John D.
    BLOOD, 2023, 142
  • [3] Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
    Kim, Won-Seog
    Kim, Tae Min
    Cho, Seok-Goo
    Jarque, Isidro
    Iskierka-Jazdzewska, Elzbieta
    Poon, Michelle Limei
    Prince, H. Miles
    Oh, Sung Yong
    Lim, Francesca
    Carpio, Cecilia
    Tran-Der Tan
    Ayyappan, Sabarish
    Gutierrez, Antonio
    Li, Jingjin
    Ufkin, Melanie
    Zhu, Min
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth R.
    Walewski, Jan
    BLOOD, 2022, 140 : 1070 - 1071
  • [4] Primary analysis of the Phase 2 ELM-2 study: Odronextamab in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL)
    Chong, Geoffrey
    Taszner, Michal
    Novelli, Silvana
    Cho, Seok-Goo
    Villasboas, Jose C.
    Ubieto, Ana Jimenez
    Tessoulin, Benoit
    Poon, Michelle
    Tucker, David
    Walewski, Jan
    Song, Yuqin
    Bachy, Emmanuel
    Guidez, Stephanie
    Alonso, Aranzazu
    Jagadeesh, Deepa
    Luminari, Stefano
    Mayer, Laura Magnano
    Iskierka-Jazdzewska, Elzbieta
    Tani, Monica
    Cai, Jingxian
    Uppala, Amulya
    Shariff, Saleem
    Brouwer-Visser, Jurriaan
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth
    Kim, Tae Min
    CANCER RESEARCH, 2024, 84 (07)
  • [5] Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
    Kim, Won Seog
    Kim, Tae Min
    Cho, Seok-Goo
    Jarque, Isidro
    Iskierka-Jazdzewska, Elzbieta
    Poon, Li Mei
    Prince, H. Miles
    Zhang, Huilai
    Cao, Junning
    Zhang, Mingzhi
    Tessoulin, Benoit
    Oh, Sung Yong
    Lim, Francesca
    Carpio, Cecilia
    Tan, Tran-Der
    Ayyappan, Sabarish
    Gutierrez, Antonio
    Cai, Jingxian
    Ufkin, Melanie
    Sharif, Saleem
    Brouwer-Visse, Jurriaan
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth
    Walewski, Jan
    NATURE CANCER, 2025, 6 (03) : 528 - 539
  • [6] Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
    Kim, Tae Min
    Taszner, Michal
    Cho, Seok-Goo
    Novelli, Silvana
    Le Gouill, Steven
    Poon, Michelle Limei
    Villasboas, Jose C.
    Champion, Rebecca
    Bachy, Emmanuel
    Guidez, Stephanie
    Alonso, Aranzazu Alonso
    Jagadeesh, Deepa
    Merli, Michele
    Tucker, David
    Cai, Jingxian
    De Oliveira, Carolina Leite
    Zhu, Min
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth R.
    Luminari, Stefano
    BLOOD, 2022, 140 : 2280 - 2282
  • [7] Health-Related Quality of Life and Symptoms in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Odronextamab Monotherapy in the Phase 2 ELM-2 Study
    Iskierka-Jazdzewska, Elzbieta
    Kim, Won Seog
    Cho, Seok-Goo
    Kim, Tae Min
    Jarque, Isidro
    Robak, Tadeusz
    Poon, Michelle
    Prince, H. Miles
    Yong, Sung
    Lim, Francesca
    Carpio, Cecilia
    Tan, Tran-Der
    Ayyappan, Sabarish
    Gutierrez, Antonio
    Zhang, Huilai
    Cao, Junning
    Zhang, Mingzhi
    Tessoulin, Benoit
    Li, Jingjin
    Ivanescu, Cristina
    BLOOD, 2023, 142
  • [8] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Kalakonda, Nagesh
    Cavallo, Federica
    Follows, George
    Goy, Andre
    Vermaat, Joost S. P.
    Casasnovas, Olivier
    Lavee, Orly
    Maerevoet, Marie
    Zijlstra, Josee
    Bakhshi, Sameer
    Bouabdallah, Reda
    Choquet, Sylvain
    Gurion, Ronit
    Hill, Brian
    Jaeger, Ulrich
    Sancho, Juan-Manuel
    Schuster, Michael
    Thieblemont, Catherine
    De la Cruz, Fatima
    Egyed, Miklos
    Mishra, Sourav
    Offner, Fritz
    Vassilakopoulos, Theodoros
    Warzocha, Krzysztof
    McCarthy, Daniel
    Ma, Xiwen
    Corona, Kelly
    Saint-Martin, Jean-Richard
    Joshi, Anita
    Shah, Jatin
    Van den Neste, Eric
    Canales, Miguel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
  • [9] Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up
    Villasboas, Jose. C.
    Kim, Tae Min
    Taszner, Michal
    Novelli, Silvana
    Cho, Seok-Goo
    Merli, Michele
    Ubieto, Ana Jimenez
    Tessoulin, Benoit
    Poon, Michelle
    Walewski, Jan
    Yi, Shuhua
    Song, Yuqin
    Chong, Geoffrey
    Luminari, Stefano
    Bachy, Emmanuel
    Guidez, Stephanie
    Alonso, Aranzazu
    Jagadeesh, Deepa
    Zhang, Wei
    Magnano, Laura
    Iskierka-Jazdzewska, Elzbieta
    Tani, Monica
    Cai, Jessica
    Uppala, Amulya
    Shariff, Saleem
    Chi, Lei
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth
    Tucker, David
    BLOOD, 2023, 142
  • [10] Health-related quality of life (HRQoL), functioning, and symptoms with odronextamab monotherapy in patients (pts) with relapsed or refractory follicular lymphoma (R/R FL) by POD24 status in the ELM-2 study.
    Villasboas, Jose Caetano
    Mayer, Laura Magnano
    Tessoulin, Benoit
    Cho, Seok-Goo
    Taszner, Michal
    Novelli, Silvana
    Luminari, Stefano
    Merli, Michele
    Ubieto, Ana Jimenez
    Poon, Michelle
    Tucker, David
    Walewski, Jan Andrzej
    Ivanescu, Cristina
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth R.
    Harnett, James
    Kamat, Siddhesh
    Kim, Tae Min
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345